Current management of reflex sympathetic dystrophy syndrome (complex regional pain syndrome type I).
Although no major advances have occurred in the curative treatment of reflex sympathetic dystrophy syndrome (RSDS), new pathogenic insights may soon lead to innovative approaches, which may also prove effective in alleviating some forms of neuropathic pain. Preventing nerve compression and ischemia-reperfusion injury constitute valuable measures for preventing RSDS. Vitamin C administration can also prevent RSDS, together with clonidine in high-risk patients. Short-term glucocorticoid therapy has been found effective in preventing RSDS after stroke but has not been evaluated in other situations. Beneficial effects of bisphosphonates have been documented in several placebo-controlled trials. Placebo-controlled trials of ketamine and spinal cord stimulation are in order to confirm or refute the promising results obtained in open-label studies. Mirror visual feedback was introduced recently for the rehabilitation of patients with RSDS but needs to be evaluated in randomized controlled trials.
Berthelot
Jean-Marie
JM
Service de rhumatologie, Hôtel-Dieu, CHU de Nantes, 1, place Alexis, Nantes cedex 01, France. jeanmarie.berthelot@chu-nantes.fr
D000700:Analgesics / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D005246:Feedback; D006801:Humans; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy* / Q000517:prevention & control*; D013565:Sympatholytics / Q000627:therapeutic use*; D014815:Vitamins / Q000627:therapeutic use
D000700:Analgesics; D004164:Diphosphonates; D013565:Sympatholytics; D014815:Vitamins